Navigation Links
Rigel Earns Milestone Payments From AstraZeneca
Date:9/29/2010

une inflammatory disease that causes damage to the joints and other organs. It is a major cause of disability, affecting approximately 1 in 100 people, and is also associated with reduced life expectancy, especially if not adequately treated.

Fostamatinib, which has completed a comprehensive phase 2 program, is the first oral spleen tyrosine kinase (syk) inhibitor in development as a novel therapeutic approach for RA. Inhibiting syk is thought to block signaling in multiple cell types involved in inflammation and tissue degradation in RA.   Inhibition of syk signaling is therefore believed to be a very attractive research approach to RA treatment.

About Rigel Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune disorders, as well as muscle and metabolic diseases. Rigel's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market its product candidates. Current product development programs include fostamatinib (R788), an oral syk inhibitor that has started its phase 3 clinical trial program for rheumatoid arthritis, and R343, an inhaled syk inhibitor that is in clinical trials for asthma.

Rigel Forward-Looking StatementsThis press release contains "forward-looking" statements, including, without limitation, statements related to the scope of the phase 3 clinical program of R788 (fostamatinib) and the filing of new drug applications, including the timing thereof. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "expected", "believed" and similar expressions are intended to identify these forward-looking statements. These forward-looking stateme
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Rigel to Host Update Conference Call
2. Rigel Announces Third Quarter 2008 Financial Results and Clinical Update
3. Rigel to Present at the 2008 Credit Suisse Healthcare Conference
4. Rigel to Host Conference Call to Discuss Phase 2 Study Results of R788 in Lymphoma Presented at ASH
5. Rigel to Participate at the RBC Capital Markets Healthcare Conference
6. Rigel to Present at Citis Biotech Day
7. Rigel Announces First Quarter 2009 Financial Results
8. Rigel Announces Pricing of Public Offering of 13,000,000 Shares of Common Stock
9. Aerospace engineer earns Oak Ridge Associated Universities Ralph Powe Junior Faculty Award
10. InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
11. Advanced Pest Control Earns Quality Pro Designation for General Pest Control Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... July 10, 2014 EvoDerma ’s NOOME ... This rejuvenating device now comes with a second treatment cup ... time. , The new cup is thinner on the edges ... to target rough, thin and uneven surfaces on the face, ... for a stimulating treatment on areas such as the cheeks ...
(Date:7/10/2014)... , July 10, 2014  Franciscan St. ... of capnography for respiratory monitoring outside the ... healthcare leaders in embracing state-of-the-art patient safety ... patients are breathing and can alert medical ... measuring the amount of carbon dioxide the ...
(Date:7/10/2014)... , July 10, 2014  Kainos Capital, a ... brands, today announced that it has acquired the Slim-Fast ... in the business. Terms of the transaction were not ... and meal replacement business that markets ready-to-drink shakes, powders, ... North America and in the ...
(Date:7/10/2014)... -- Research and Markets ( http://www.researchandmarkets.com/research/s3bqj2/photonic ) has ... Integrated Circuit (Monolithic Integration, Hybrid Integration, Module Integration) ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... traces its roots in the latter half of ... went unexplored and unfulfilled for several decades owing ...
Breaking Biology Technology:Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2Kainos Capital Acquires Slim-Fast From Unilever 2International Photonic Integrated Circuit (Monolithic Integration, Hybrid Integration, Module Integration) Market - Forecasts to 2019 2
... , ... Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) and ... entered into a licensing agreement for antibody therapeutic rights under ... Under the terms of the agreement, Affitech will license exclusive ...
... , ROCKVILLE, Md., July 22 ... selection of a Respiratory Syncytial Virus (RSV) vaccine candidate that ... Investigational New Drug (IND) application. As previously announced, Novavax ... of which have successfully induced antibody responses in mice. ...
... , , , ... Biotech, Inc., a company personalizing spine care through the development ... that they have entered into a collaboration that allows Axial ... Population Database (UPDB). UPDB is a genealogical and family history ...
Cached Biology Technology:Peregrine Pharmaceuticals Licenses Anti-VEGF Antibodies to Affitech 2Peregrine Pharmaceuticals Licenses Anti-VEGF Antibodies to Affitech 3Peregrine Pharmaceuticals Licenses Anti-VEGF Antibodies to Affitech 4Peregrine Pharmaceuticals Licenses Anti-VEGF Antibodies to Affitech 5Novavax Announces Selection of a Respiratory Syncytial Virus Vaccine Candidate for Advanced Preclinical Studies 2Novavax Announces Selection of a Respiratory Syncytial Virus Vaccine Candidate for Advanced Preclinical Studies 3Novavax Announces Selection of a Respiratory Syncytial Virus Vaccine Candidate for Advanced Preclinical Studies 4Axial Biotech Enters Partnership with the University of Utah to Utilize the Utah Population Database to Develop Personalized Diagnostic Tests for Spine Disorders 2Axial Biotech Enters Partnership with the University of Utah to Utilize the Utah Population Database to Develop Personalized Diagnostic Tests for Spine Disorders 3
(Date:7/10/2014)... Research and Markets ( http://www.researchandmarkets.com/research/h7h8lq/gesture ) ... Gesture Recognition & Touch-Less Sensing (2D, 3D, Ultrasonic, ... report to their offering ... Touch-Less Sensing Market to Grow Exponentially. Touch-less sensing ... the companies were unable to leverage this technology ...
(Date:7/10/2014)... 2014 Fingerprint Cards, (FPC,s) ... win (DW). An Asian OEM has selected FPC1021 for a ... in August 2014.   FPC is proud to ... a planned date for start of mass production in August ... SEK 5M, for delivery in the first half of July. ...
(Date:7/10/2014)... belongs to the large, mainly tropical flowering plant family Melastomataceae ... the family rely on bees for their pollination. Only about ... vertebrates. The flowers of Axinaea appear in clusters ... of the different species are pink, yellow, orange or red. ... contrasting colours of their bulbous appendages. The pollination mechanism of ...
Breaking Biology News(10 mins):Global Gesture Recognition & Touch-Less Sensing (2D, 3D, Ultrasonic, IR, Capacitive) Market - Forecasts to 2020 2FPC Wins DW and Initial Ramp Order for FPC1021 Touch Sensor for Flagship Smartphone from Asian OEM 2Novel type of bird pollination mechanism discovered in South America 2
... ... Presidential Early Career Award for Scientists and Engineers (PECASE). The award ... scientists and engineers in the early stages of their careers. ... significant award," said Jane Lubchenco, Ph.D., under secretary of commerce for ...
... Researchers at the University of Missouri have identified a ... may provide new insight into the debilitating and fatal ... "Critical communication occurs at the point where nerves and ... nerves and muscles is disrupted, muscles do not work ...
... -- The National Institutes of Health (NIH) has awarded a ... research into risk factors for spina bifida and related congenital ... or brain is not fully enclosed. The research will ... E. Mason at Weill Cornell Medical College. Dr. Ross is ...
Cached Biology News:President to honor high achieving, early career NOAA scientists 2MU researchers find new insight into fatal spinal disease 2NIH awards $5.5 million grant to Weill Cornell for research into preventing spina bifida 2NIH awards $5.5 million grant to Weill Cornell for research into preventing spina bifida 3